Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Latest predictions
-
02.10.20
-
20.09.20
buy
€16.00
06.08.20
buy
€12.00
02.03.20
buy
-
23.12.19
buy
€23.90
07.08.19
buy
Your prediction

Sangamo Therapeutics Inc. Stock

Heavy losses for Sangamo Therapeutics Inc. today as the stock fell by -€0.360 (-3.100%).
With 6 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of €14.00 shows a positive potential of 24.246% compared to the current price of €11.27 for Sangamo Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Sangamo Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

Pros and Cons of Sangamo Therapeutics Inc. in the next few years

Pros
1
Could be worthwhile Investment >10% per year
Cons
1
Very low/no dividend yield expected

Performance of Sangamo Therapeutics Inc. vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Sangamo Therapeutics Inc. -3.100% -8.857% -21.886% 78.070% -16.919% -31.195% 82.830%
Kezar Life Sciences -3.180% 0.000% -2.740% 60.150% 7.576% - -
MannKind Corp. -0.030% 10.580% 7.701% 99.119% 8.537% 28.816% -14.870%
Rocket Pharmaceuticals Inc -3.080% -0.452% -9.465% 129.167% -1.786% 354.545% 49.355%

Comments

Buy Sangamo Therapeutics Inc.

Buy Sangamo Bioscienes

Other discussions about Sangamo Therapeutics Inc. Stock

Trading Sangamo Bioscienes

Trading Sangamo Bioscienes

New thread Forum

News

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s

Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:




  • 29th Annual Credit Suisse Virtual

Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights.



“We are pleased with the clinical

Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:




  • Jefferies Virtual Gene Therapy /

Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:




  • Wells Fargo 2020 Virtual Healthcare

Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August

Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.



“We are very excited about our global

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize

Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market